Journey Medical Corporation reported a total revenue of $61.9 million for the fiscal year ending December 31, 2025, marking a 10% increase from $56.1 million in the previous year. This growth was primarily driven by the successful launch of Emrosi, a new product approved by the FDA for the treatment of inflammatory lesions of rosacea, which generated $14.7 million in its first year of sales. However, the company faced challenges with its established products, particularly Accutane, which saw a revenue decline of 34%, contributing to a net loss of $11.4 million, an improvement from the $14.7 million loss reported in 2024.
In terms of operational changes, Journey Medical's product portfolio now includes eight FDA-approved drugs, with Emrosi being a significant addition following its approval on November 1, 2024. The company began promoting Emrosi in April 2025, leveraging its existing sales team. Additionally, Journey Medical joined the Russell 2000® Index and the Russell 3000® Index in June 2025, reflecting its growth and market presence.
The company’s operational metrics indicate a strategic focus on expanding its market share in dermatology. As of December 31, 2025, Journey Medical had 58 employees, with a significant portion dedicated to sales and marketing. The company has also begun supplying Amzeeq to Cutia Therapeutics for sale in China, further expanding its geographic reach. However, the company reported a substantial increase in its gross-to-net sales accruals, which rose to $18.7 million, reflecting the impact of promotional allowances and rebates associated with the launch of Emrosi.
Looking ahead, Journey Medical faces substantial challenges, including the need for additional funding to support its operations and product development. The company has expressed substantial doubt about its ability to continue as a going concern for at least the next twelve months, primarily due to recurring losses. Management is exploring various financing options, including potential equity offerings and debt financing, to bolster its capital structure and support ongoing operations. The company’s future growth will depend on its ability to successfully commercialize its current products and any future product candidates while navigating the competitive landscape of the pharmaceutical industry.
About Journey Medical Corp
Journey Medical Corporation is a pharmaceutical company specializing in the development, marketing, and sale of FDA-approved dermatology products. Its portfolio includes treatments for rosacea, acne, hyperhidrosis, fungal infections, and skin conditions, primarily sold through specialty pharmacies and distributors in the U.S. The company leverages licensing, acquisitions, and proprietary technologies to innovate and expand its product offerings in the dermatology market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.